ArticleBMJ (Clinical research ed.)2002
Efficacy, safety, and cost of new anticancer drugs.
Article in BMJ (Clinical research ed.), 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- 1Molecules (Basel, Switzerland) · 2022Review
- Enhanced Proapoptotic Effects of Water Dispersed Complexes of 4-Thiazolidinone-Based Chemotherapeutics with a PEG-Containing Polymeric Nanocarrier.Nanoscale research letters · 2019Article
- Patients not patents: Drug research and development as a public enterprise.European journal of clinical investigation · 2018Article
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.BMJ (Clinical research ed.) · 2017Article
- Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.Frontiers in pharmacology · 2017Article
- Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.PloS one · 2017Article
- Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs.Frontiers in pharmacology · 2016Article
- Market-access agreements for anti-cancer drugs.Journal of the Royal Society of Medicine · 2015Article
- Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?Social science & medicine (1982) · 2015Review
- A new approach to psychiatric drug approval in Europe.PLoS medicine · 2013Article
- EMA's reflection on placebo does not reflect patients' interests.European journal of clinical pharmacology · 2012Article
- Article
- Does the development of new medicinal products in the European Union address global and regional health concerns?Population health metrics · 2010Article
- Toward a definition of pharmaceutical innovation.Open medicine : a peer-reviewed, independent, open-access journal · 2008Article
- Oncolytic viruses in cancer therapy.Cancer letters · 2007Review
- Haematological anticancer drugs in Europe: any added value at the time of approval?European journal of clinical pharmacology · 2007Article
- An update on the first decade of the European centralized procedure: how many innovative drugs?British journal of clinical pharmacology · 2006Article
- Oncology care planning. Elements for care quality and management improving.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2006Article
- Heart failure induced by non-cardiac drugs.Drug safety · 2006Review
- Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.British journal of cancer · 2005Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.